Navigation Links
Long-term Use of Antiepileptic Drug Vimpat® (Lacosamide) C-V Reduced Seizure Frequency and Severity and Improved Health-related Quality of Life Measures
Date:12/5/2011

sented at AES used the following measurement scales:

  • Quality of Life in Epilepsy scale (QOLIE-31) is an epilepsy-specific assessment with 31 questions that ask patients about their health-related quality of life.  Responses to the questions are ranked on a scale of 0 (worst possible quality of life) to 10 (best possible quality of life).
  • Seizure Severity Questionnaire (SSQ) allows patients to review various aspects of their seizures, such as altered consciousness and cognitive, emotional, and physical effects.
  • Patient Global Impression of Change (PGIC) is a scale that allows patients to rank how much they think their condition has changed during the treatment period of the trial.  The scale ranges from 0 (much better) to 10 (much worse).

Summary of Vimpat® Data:

Abstract 2.233: Evaluation of Long-Term Treatment with Lacosamide for Partial-Onset Seizures: A Pooled Analysis of Open-Label Extension Trials

This analysis of pooled data from three open-label extension trials examined the effects of open-label treatment with lacosamide exposure up to 8 years in patients with partial-onset seizures.  A total of 1,054 patients initiated open-label lacosamide treatment, representing 2,997.8 patient-years exposure.  Results showed that treatment with lacosamide up to eight years was generally well tolerated and associated with a reduction in seizure frequency and maintenance of efficacy over time.  Additionally, no new safety concerns were identified related to long-term treatment with lacosamide. 

The median modal dose of lacosamide (i.e., the dose that patients used most often during the trial) was 400mg/day for a minimum treatment duration of three days up to a maximum duration of 2,913 days (~8 years).  The median maximum daily dose was 500 m
'/>"/>

SOURCE UCB, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Three-Year Clinical Outcomes from Use of Genous™ Stent in Large, Real-World Patient Population Demonstrate Long-Term Safety and Efficacy
2. Merz research Shows Long-term Benefits for Patients With Dystonia
3. AdCare Health Systems Selects Remedi SeniorCare for Long-Term Care Pharmacy Solutions
4. Clinical Data Demonstrates Long-Term Safety of Boston Scientifics Alair[TM]Bronchial Thermoplasty System
5. Novus Scientific Announces the Worlds 1st Long-Term Absorbable Mesh as an Alternative to Non-Absorbable Synthetic Mesh
6. Rescheduled Webcast: Isis Pharmaceuticals Hosts Dr. John Kastelein to Review Mipomersen Long-term Data Recently Presented at ESC Congress 2011
7. Webcast Alert: Isis Pharmaceuticals Hosts Dr. John Kastelein to Review Mipomersen Long-term Data Recently Presented at ESC Congress 2011
8. NIH-Funded Study Demonstrates That Patients Receiving New CPR Devices (ResQPOD® and ResQPump™) and Cooling Have Improved Long-Term Brain Function Following Cardiac Arrest
9. Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
10. Novocure Announces Long-Term Supply Agreement With ITT Corporation for Ceramic Sensor Technology
11. Analysis Compares Cost-Effectiveness of Premixed Insulin Analogs to Long-Acting Insulin Analogs in the Long-Term Treatment of Type 2 Diabetes in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  MedScope ( www.medscope.org ), ... nominated for a 2015 Connected World magazine ... Response System (mPERS), that can be used anywhere, anytime. ... partner.  In nominating MedScope, Landon ...
(Date:1/23/2015)... PHILADELPHIA , Jan. 23, 2015  Pete Rose, baseball,s all-time ... joint and arthritis pain reliever Myoflex, Ducere Pharma has announced. ... and we are excited to have him on board with ... . "He is a legendary player who is known across ...
(Date:1/23/2015)... SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, ... where its Phase I trial of Lixte,s lead compound, LB‑100, ... institutions. John S. Kovach , M.D., the ... was planned to be completed at a single site. Accrual ...
Breaking Medicine Technology:MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2Pete Rose bets on Myoflex to relieve aches and pains 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... Premier Purchasing Partners, LP, a leading healthcare purchasing network, has awarded a ... Management Division of Smith & Nephew, Inc., a subsidiary of Smith & ... hospitals and 64,000 other healthcare sites.  The three-year contract begins on ... , , ...
... announced today the launch of the EDUCARE (EDUcation for Cancer in African ... provide support to help combat the growing cancer epidemic in sub-Saharan Africa. ... The EDUCARE project ... a wider initiative to build regional training networks in cancer control and ...
Cached Medicine Technology:Smith & Nephew Awarded Patient Cleansing and Skin Care Contract with Premier 2Smith & Nephew Awarded Patient Cleansing and Skin Care Contract with Premier 3Roche Announces Joint Initiative to Train Healthcare Workers in Africa's Fight Against Cancer 2Roche Announces Joint Initiative to Train Healthcare Workers in Africa's Fight Against Cancer 3Roche Announces Joint Initiative to Train Healthcare Workers in Africa's Fight Against Cancer 4
(Date:1/22/2015)... EAGAN, Minn. (PRWEB) January 22, 2015 Blue ... discover those Minnesotans who exemplify what it means to “Live ... a chance for people to share their stories about how ... adversity or simply inspired others by living in the moment. ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo and ... federal multidistrict litigation underway in U.S. District Court, District ... Order dated January 20th, the Court has remanded a ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
(Date:1/22/2015)... Payday lending practices in four southern states worsen ... to the states that permit them, according to a ... Race and Wealth. , While they generate hundreds of ... the same time substantially depress economic activity, according to ...
(Date:1/22/2015)... a new blog post explaining the importance of keeping a first ... an auto insurance policy . , Clients who driver safer ... vehicle insurance policies. The safety a vehicle offers from its driver ... this, drivers should always carry a first aid kit in their ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... Amneal Pharmaceuticals is,pleased to announce that it ... USP in strengths of 5mg, 10mg, 25mg and ... an AA-Rated,therapeutically equivalent alternative to Urecholine(R) (a trademark ... breakthrough for Amneal, who is,one of the very ...
... Ill., Nov. 29 Abbott (NYSE:,ABT)announced today that ... Food and Drug Administration (FDA) recommended approval for ... V is a,next-generation drug eluting stent intended for ... The FDA advisory committee voted to recommend the ...
... (NYSE: BSX ) today welcomed the recommendation ... panel to approve with conditions the,PROMUS(TM) / XIENCE(TM) ... V stent systems are identical products, sold respectively,by ... stent,systems would be covered by the same FDA ...
... Nov. 29 As early detection and treatments,improve, ... Autism and,Asperger,s Syndrome are considering higher education., ... of an aging population,with autism, others have turned ... with Autism and Developmental Disabilities (AHEADD), to,enhance their ...
... 2007 Traditionally, clinicians have relied on information ... as the primary means of assessing patients symptoms ... arise if important symptoms go unreported during those ... new study by researchers at Memorial Sloan-Kettering Cancer ...
... Experts Address Smart Solutions to Keep Program,Accessible and Affordable, ... Medical Society hosted a panel discussion with local voters ... Medicare could,leave the program after scheduled pay cuts go ... people in the program to find a doctor. But ...
Cached Medicine News:Health News:FDA Advisory Committee Recommends Approval of Abbott's XIENCE(TM) V Drug Eluting Stent System 2Health News:Boston Scientific Welcomes FDA Panel Recommendation to Approve PROMUS(TM) / XIENCE(TM) V Everolimus-eluting Coronary Stent System 2Health News:Boston Scientific Welcomes FDA Panel Recommendation to Approve PROMUS(TM) / XIENCE(TM) V Everolimus-eluting Coronary Stent System 3Health News:Autism U: As College Application Deadlines Near, Growing Adult Autism Population Focuses on Higher Education 2Health News:Cancer patients may benefit from reporting symptoms online in real time 2Health News:Cancer patients may benefit from reporting symptoms online in real time 3Health News:Cancer patients may benefit from reporting symptoms online in real time 4Health News:AARP Pennsylvania Hosts Panel on Strengthening Medicare 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: